Juan Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Cai has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Xiying Li
Department of Blood Transfusion, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021
63 shared publications - Jiarui Yao
Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
62 shared publications - Le Tang
Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
62 shared publications - Rongrong Luo
Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
62 shared publications - Xiaohong Han
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
62 shared publications - Yuankai Shi
Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
62 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Comparisons of positive rate between differential autoantibody signatures and tumor biomarkers in Early-LUAD.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 differential autoantibody signatures positively correlated with RDW.CV.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S5. Correlation between differential autoantibody signatures from Early-LUAD versus BLD and blood routine test. Some of the 143 differential autoantibody signatures positively correlated with RDW.CV.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S3. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus NHC. Each boxplot represents an individual peptide signature in the two sample sets.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S3. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus NHC. Each boxplot represents an individual peptide signature in the two sample sets.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Corresponding signal of previous reported autoantibodies for early lung cancer detection were evaluated in our study cohort with both HuProtTM protein microarray (detail data not shown) and peptide array. All peptides were aligned to 10 proteins using blastp method, 246 peptides were mapped under the set of e-value of 1 and identity of 90. Accumulated peptide signal was set as autoantibody signal of corresponding antigen protein. Nine autoantibodies had effective testing value in HuprotTM. a.t test P value of autoantibodies signals for Early-LUAD versus NHC from peptide array and HuProtTM detection respectively. Two autoantibodies from peptide array and 2 autoantibodies from HuProtTM showed higher signal in Early-LUAD group under P <0.05. Five autoantibodies from peptide array and 2 autoantibodies from HuProtTM showed higher signal in Early-LUAD group under P < 0.1.b.Volcano plot of peptides signals corresponding to 10 autoantigens. X-axis represents the log10 of the fold change, y-axis represents -log10 (P adjust) for Early-LUAD versus NHC. Significantly up-regulated and down-regulated peptides in Early-LUAD group are shown in light red and blue. Two hundred and forty-six peptides mapped to the 10 autoantibodies were shown in green, and 8 significantly upregulated peptides in Early-LUAD shown in green cross. No intersection between the green mapped signals and the peptides used for classifier model (dark red).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Corresponding signal of previous reported autoantibodies for early lung cancer detection were evaluated in our study cohort with both HuProtTM protein microarray (detail data not shown) and peptide array. All peptides were aligned to 10 proteins using blastp method, 246 peptides were mapped under the set of e-value of 1 and identity of 90. Accumulated peptide signal was set as autoantibody signal of corresponding antigen protein. Nine autoantibodies had effective testing value in HuprotTM. a.t test P value of autoantibodies signals for Early-LUAD versus NHC from peptide array and HuProtTM detection respectively. Two autoantibodies from peptide array and 2 autoantibodies from HuProtTM showed higher signal in Early-LUAD group under P <0.05. Five autoantibodies from peptide array and 2 autoantibodies from HuProtTM showed higher signal in Early-LUAD group under P < 0.1.b.Volcano plot of peptides signals corresponding to 10 autoantigens. X-axis represents the log10 of the fold change, y-axis represents -log10 (P adjust) for Early-LUAD versus NHC. Significantly up-regulated and down-regulated peptides in Early-LUAD group are shown in light red and blue. Two hundred and forty-six peptides mapped to the 10 autoantibodies were shown in green, and 8 significantly upregulated peptides in Early-LUAD shown in green cross. No intersection between the green mapped signals and the peptides used for classifier model (dark red).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S4. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus BLD. Each boxplot represents an individual peptide signature in the two sample sets.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Figure S4. Autoantibodies differentially expressed in plasma samples from patients with Early-LUAD versus BLD. Each boxplot represents an individual peptide signature in the two sample sets.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Random forest model and GO enrichment. a, Schematic plot of random forest; b, GO terms enriched by the matched proteins of differential peptide probes.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Random forest model and GO enrichment. a, Schematic plot of random forest; b, GO terms enriched by the matched proteins of differential peptide probes.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Corresponding abbreviated number for differential peptides probes in correlation plot.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Corresponding abbreviated number for differential peptides probes in correlation plot.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Reproducibility of peptides microarray. a, Heatmap of spearman correlation of 47 samples tested with 3 technical repeats within one batch. b. Heatmap of spearman correlation of 6 samples repeatedly tested across 3 batches.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Reproducibility of peptides microarray. a, Heatmap of spearman correlation of 47 samples tested with 3 technical repeats within one batch. b. Heatmap of spearman correlation of 6 samples repeatedly tested across 3 batches.
- Open Access
- 11 December 2024
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 22 (6)
A Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules
Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0–I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG/IgM candidates, and focused microarray further verified 55 significantly elevated IgG/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD/NHC/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules ≤ 8 mm, 9–20 mm, and > 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 ≤ CRS ≤ 25 and CRS > 25 indicated a higher risk of Early-LUAD compared to the reference (CRS < 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18–8.76] and 9.05 (95% CI: 5.40–15.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.
- 11 December 2024
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 22 (6)
Open AccessA Novel IgG–IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules
Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0–I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG/IgM candidates, and focused microarray further verified 55 significantly elevated IgG/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD/NHC/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules ≤ 8 mm, 9–20 mm, and > 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 ≤ CRS ≤ 25 and CRS > 25 indicated a higher risk of Early-LUAD compared to the reference (CRS < 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18–8.76] and 9.05 (95% CI: 5.40–15.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.
- Open Access
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Random forest model and GO enrichment. a, Schematic plot of random forest; b, GO terms enriched by the matched proteins of differential peptide probes.
- 1 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
Random forest model and GO enrichment. a, Schematic plot of random forest; b, GO terms enriched by the matched proteins of differential peptide probes.